NCT06926816 Universal Genetic Testing for Cancer Risk Reduction
| NCT ID | NCT06926816 |
| Status | Recruiting |
| Phase | — |
| Sponsor | NYU Langone Health |
| Condition | Genetic Testing |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-03-04 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2025-03-04 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to see if offering genetic testing for cancer-related genes is feasible and acceptable for patients presenting for gynecology clinic visits, instead of needing to see specialized providers or needing to meet specific criteria. The primary aim to assess the proportion of patients who undergo genetic testing, and the proportion of patients with pathogenic variants.
Eligibility Criteria
Inclusion Criteria: 1. Female patients between ages of 25-39 years at the time of visit 2. Receive gynecologic care at an affiliated NYU Langone Health (NYULH) site listed in this protocol. Exclusion Criteria: 1. Personal history of ovarian, fallopian tube, primary peritoneal, or uterine cancers 2. Previously undergone germline testing for ovarian cancer risk variants (prior commercial saliva-based kits, such as 23andMe, are acceptable) 3. History of bilateral salpingo-oophorectomy 4. Visit related to pregnancy or immediately postpartum (within 2 weeks)
Contact & Investigator
Bhavana Pothuri, MD, MS
PRINCIPAL INVESTIGATOR
NYU Langone Health
Frequently Asked Questions
Who can join the NCT06926816 clinical trial?
This trial is open to female participants only, aged 25 Years or older, up to 39 Years, studying Genetic Testing. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06926816 currently recruiting?
Yes, NCT06926816 is actively recruiting participants. Contact the research team at Bhanava.pothuri@nyulangone.org for enrollment information.
Where is the NCT06926816 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06926816 clinical trial?
NCT06926816 is sponsored by NYU Langone Health. The principal investigator is Bhavana Pothuri, MD, MS at NYU Langone Health. The trial plans to enroll 600 participants.